Search

Displaying results 6641 - 6650 of 10000 in total
  1. Drug

    Edotecarin

    go.drugbank.com/drugs/DB04882
    Investigational

    Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.

  2. Drug

    Anisodamine

    go.drugbank.com/drugs/DB11785
    Investigational

    Anisodamine has been investigated for the treatment of Intestinal Diseases.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    in mice) studies. … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.

  4. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

  5. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  6. Drug

    Ocaperidone

    go.drugbank.com/drugs/DB06229
    Experimental

  7. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.

  8. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It has never been approved for use in the U.S. or Canada. … It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity.

  9. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  10. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.